TM4SF20 Inhibitors
Chemical inhibitors of TM4SF20 can exert their inhibitory action through various mechanisms, targeting different kinases and enzymes involved in the signaling pathways with which TM4SF20 is associated. Bisindolylmaleimide I and Gö 6983 are inhibitors that specifically target protein kinase C (PKC). By inhibiting PKC, these chemicals can decrease the phosphorylation of proteins that are part of the signaling pathways interacting with TM4SF20. This reduction in phosphorylation can inhibit the functional activity of TM4SF20 in signal transduction. Ro-31-8220, like the previous inhibitors, also targets PKC, leading to decreased activity of this kinase and consequently reducing the phosphorylation levels of proteins that are essential for the functional expression of TM4SF20 within cellular signaling. Staurosporine operates as a broad-spectrum kinase inhibitor, affecting a range of kinases that are upstream in the signaling pathways involving TM4SF20, thereby inhibiting the activation of these pathways and the function of TM4SF20.
LY294002 and Wortmannin are inhibitors of phosphoinositide 3-kinases (PI3K), which play a role in the PI3K/Akt pathway connected to TM4SF20. By blocking this pathway, these inhibitors can reduce the phosphorylation and activation of downstream proteins, leading to an inhibition of TM4SF20's role in this signaling cascade. PD98059 and U0126, both MEK inhibitors, act by inhibiting the MAPK/ERK pathway, which is another pathway associated with TM4SF20. The inhibition of MEK leads to a decrease in the activation of ERK, a key component of this pathway, which subsequently inhibits TM4SF20-related signaling. SP600125 and SB203580 are inhibitors targeting different aspects of the MAPK pathway: SP600125 inhibits JNK, while SB203580 specifically inhibits p38 MAP kinase. By suppressing the activity of these kinases, the signaling through pathways where TM4SF20 is functionally involved is diminished. Finally, Y-27632 and ML7 target the actin cytoskeleton dynamics, with Y-27632 inhibiting the Rho-associated protein kinase (ROCK) and ML7 inhibiting myosin light chain kinase (MLCK). These inhibitors can disrupt the regulation of the actin cytoskeleton and cellular processes that TM4SF20 may affect, thus inhibiting the functional role of TM4SF20 in these processes.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $105.00 $242.00 | 36 | |
Bisindolylmaleimide I (BIM I) is a specific inhibitor of protein kinase C (PKC). TM4SF20 is involved in signaling pathways that include PKC-mediated phosphorylation. By inhibiting PKC, BIM I can reduce the phosphorylation of proteins that interact with TM4SF20, leading to a functional inhibition of TM4SF20's role in signal transduction processes. | ||||||
Gö 6983 | 133053-19-7 | sc-203432 sc-203432A sc-203432B | 1 mg 5 mg 10 mg | $105.00 $299.00 $474.00 | 15 | |
Gö 6983 is a pan-PKC inhibitor that can inhibit multiple isoforms of PKC. As TM4SF20 is associated with PKC-regulated pathways, the inhibition of PKC by Gö 6983 can lead to a decrease in the phosphorylation state of proteins within the pathway, thereby inhibiting the functional activity of TM4SF20. | ||||||
Ro 31-8220 | 138489-18-6 | sc-200619 sc-200619A | 1 mg 5 mg | $92.00 $245.00 | 17 | |
Ro-31-8220 is another potent PKC inhibitor which can impact the function of TM4SF20 by inhibiting PKC-dependent signaling pathways. By reducing the activity of PKC, Ro-31-8220 decreases the phosphorylation levels of proteins that are necessary for TM4SF20 to exert its function within cellular signaling. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a broad-spectrum kinase inhibitor that targets a wide range of kinases, including those that are upstream of the pathways TM4SF20 is involved in. By inhibiting these kinases, staurosporine can reduce the activation of TM4SF20-associated pathways, thereby inhibiting TM4SF20's functional role. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a specific inhibitor of PI3K, which is involved in a pathway linked with TM4SF20. Inhibition of PI3K leads to a reduction in Akt phosphorylation, a process that is important for the activation of several downstream proteins that might interact with TM4SF20, therefore inhibiting its function. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another PI3K inhibitor that can indirectly inhibit TM4SF20 by blocking the PI3K/Akt pathway, leading to decreased activity of downstream effectors that are crucial for TM4SF20's functionality in cellular signaling processes. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is an inhibitor of MEK, which acts upstream in the MAPK/ERK pathway, a pathway that TM4SF20 is involved in. By inhibiting MEK, PD98059 can reduce the activation of ERK and thus inhibit the downstream signaling that involves TM4SF20. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is also a MEK inhibitor, functioning similarly to PD98059, and can thereby inhibit TM4SF20 by reducing the activity of the MAPK/ERK pathway, which is connected to TM4SF20's functional role in cellular signaling. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, part of the MAPK pathway. TM4SF20, being associated with the MAPK pathway, can be functionally inhibited by SP600125 through the reduction of JNK-mediated signaling events which may involve TM4SF20. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 specifically inhibits p38 MAP kinase, which is another component of the MAPK pathway. The inhibition of p38 MAP kinase can lead to diminished signaling through pathways where TM4SF20 is functionally involved, resulting in its inhibition. | ||||||